Form4insider filings, from the source

SEC Form 3 · accession 0001209191-18-063530

SELLAS Life Sciences Group, Inc. · SLS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John Thomas Burns
Officer — VP, Finance & Corp Controller
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———18D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1$1,332.00holding————Jun 28, 2023Common Stock33—D
Stock Option (Right to Buy)F1$2,328.00holding————Nov 26, 2023Common Stock42—D
Stock Option (Right to Buy)F1$1,050.00holding————Jan 15, 2025Common Stock25—D
Stock Option (Right to Buy)F1$1,062.00holding————Jun 19, 2025Common Stock33—D
Stock Option (Right to Buy)F1$900.00holding————Dec 18, 2025Common Stock50—D
Stock Option (Right to Buy)F1$504.00holding————Feb 23, 2026Common Stock125—D
Stock Option (Right to Buy)F1$54.30holding————Jan 17, 2027Common Stock500—D
Stock Option (Right to Buy)F2$5.24holding————Mar 13, 2028Common Stock20,000—D

Explanation of responses